BC Extra | Jan 15, 2020
Clinical News

Denali gains on Parkinson’s results as it looks to select a Phase II candidate

Denali reported data Tuesday from pair of Phase I trials that will inform the company’s selection of a Parkinson’s disease candidate to advance to Phase II. Denali Therapeutics Inc. (NASDAQ:DNLI) gained $5.16 (29%) to $22.74...
BC Innovations | Aug 23, 2018
Translation in Brief

LRRK2 looming larger

Researchers from the University of Pittsburgh have identified a link between LRRK2 activity and idiopathic forms of Parkinson’s disease, further broadening the potential patient population for LRRK2 inhibitors in development, including two clinical compounds from...
BC Week In Review | Dec 22, 2017
Clinical News

FDA lifts hold on Denali PD candidate

Denali Therapeutics Inc. (NASDAQ:DNLI) said FDA lifted a partial clinical hold on a Phase I study of Parkinson's disease candidate DNL201. It is a leucine-rich repeat kinase 2 (LRRK2) inhibitor. The agency placed the hold...
BC Extra | Dec 21, 2017
Clinical News

FDA lifts hold on Denali's PD candidate

Denali Therapeutics Inc. (NASDAQ:DNLI) said FDA lifted a partial clinical hold on a Phase I study of Parkinson's disease candidate DNL201. It is a leucine-rich repeat kinase 2 (LRRK2) inhibitor. The agency placed the hold...
BC Week In Review | Dec 14, 2017
Financial News

Denali raises $250M in IPO

Denali Therapeutics Inc. (NASDAQ:DNLI) raised $250 million through the sale of 13.9 million shares at $18 in an IPO. Underwriters were Goldman Sachs, Morgan Stanley, JPMorgan and Evercore ISI. The price is at the midpoint...
BC Extra | Dec 8, 2017
Financial News

Denali climbs after $250M IPO

Denali Therapeutics Inc. (NASDAQ:DNLI) jumped $3.45 (19%) to $21.45 in its first day of trading Friday after it raised $250 million through the sale of 13.9 million shares at $18 in an IPO. Underwriters were...
BC Week In Review | Nov 17, 2017
Financial News

Neurology play Denali planning $100M IPO

According to an SEC filing, neurodegenerative disease company Denali Therapeutics Inc. (South San Francisco, Calif.) is seeking to raise $100 million in an IPO on NASDAQ. Goldman Sachs, Morgan Stanley, JPMorgan and Evercore are underwriting...
BC Extra | Nov 15, 2017
Financial News

Neurology play Denali planning $100M IPO

According to an SEC filing , neurodegenerative disease company Denali Therapeutics Inc. (South San Francisco, Calif.) is seeking to raise $100 million in an IPO on NASDAQ. Goldman Sachs, Morgan Stanley, JPMorgan and Evercore are underwriting...
Items per page:
1 - 8 of 8